Novel agents and evolving strategies in Waldenström macroglobulinemia: clinical trial updates from ASH 2025
The BRUIN study (n = 80) demonstrated pirtobrutinib, a non‑covalent BTK inhibitor, as a durable option for heavily pretreated R/R WM, yielding 83 % overall response rate (ORR) and 42‑month median duration of response (DoR) among major responders at 5‑year follow‑up.
Waldenström macroglobulinemia (WM) is a rare, indolent lymphoplasmacytic lymphoma characterized by bone marrow infiltration of IgM‑secreting lymphoplasmacytic cells and associated with the MYD88(L265P) mutation in over 90 % of cases… (see full abstract above).
The study shows that non‑covalent BTK inhibitors can provide durable disease control in relapsed‑refractory Waldenström‑macroglobulinemia, a setting where resistance to covalent BTK inhibitors is common.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Waldenström Macroglobulinemia Clinical Trials
- Cost-effectiveness of zanubrutinib versus ibrutinib as first-line treatment for patients with Waldenström macroglobulinemia in China
- European Consortium for Waldenström's Macroglobulinemia
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy
- The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?